Genenta Science (NASDAQ:GNTA) Stock Price Down 4.9% – Should You Sell?

Genenta Science S.p.A. (NASDAQ:GNTA) fell 4.9% during mid-day trading on Wednesday . The stock traded as low as $4.44 and last traded at $4.70. 8,527 shares traded hands during trading, a decline of 16% from the average session volume of 10,173 shares. The stock had previously closed at $4.94.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Genenta Science in a report on Wednesday, October 2nd.

Genenta Science Price Performance

The firm’s 50 day moving average price is $4.80 and its 200-day moving average price is $4.08.

Institutional Trading of Genenta Science

An institutional investor recently bought a new position in Genenta Science stock. AlTi Global Inc. bought a new stake in Genenta Science S.p.A. (NASDAQ:GNTA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned 1.10% of Genenta Science as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 15.13% of the company’s stock.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.